<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04210284</url>
  </required_header>
  <id_info>
    <org_study_id>18-01976</org_study_id>
    <nct_id>NCT04210284</nct_id>
  </id_info>
  <brief_title>Oral Nutritional Optimization in Total Joint Arthroplasty</brief_title>
  <official_title>Oral Nutritional Optimization in Total Joint Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NYU Langone Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NYU Langone Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect on hematological markers of nutritional&#xD;
      intervention on nutritionally deficient patients following total joint replacement surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Numerous pre-operative modifiable variables have been extensively investigated for their&#xD;
      effect on outcomes in TJA. These include metabolic diseases such as diabetes mellitus,&#xD;
      obesity, and smoking status. However, nutritional status has not been as thoroughly&#xD;
      investigated; to date, no prospective randomized control study has assessed the effect of&#xD;
      oral nutritional supplementation for malnourished patients. This study will be a novel&#xD;
      investigation into the role for routine serum screening for malnutrition as well as oral&#xD;
      nutritional supplementation in TJA patients. This study could serve as a stepping stone&#xD;
      towards creating a new pathway to highlight at-risk patients and pre-operatively optimizing&#xD;
      their outcomes after TJA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2021</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in the patients' albumin, pre-albumin, and/or transferrin levels</measure>
    <time_frame>Visit 2 (2 wks pre) Visit 3 (surgery day) Visit 5 (4 weeks post)</time_frame>
    <description>Biological specimen collection and laboratory evaluations- all included patients' hematologic markers of malnutrition (albumin, pre-albumin, and transferrin) will be recorded at 2 weeks prior to surgery, the day of surgery, and 6 weeks. These blood tests can all be performed from one sample of blood at each visit. The results will then be accessed via the EMR</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">125</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Nutritional supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Given Ensure Max Protein Nutrition shake 2 weeks before surgery and continued 2 weeks after surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No Nutritional supplementation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Treatment as usual</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ensure</intervention_name>
    <description>Ensure Max Protein Shake is an over the counter available drinkable nutritional supplement. Per serving, it contains:&#xD;
160 Calories, 20 from fat&#xD;
2g Total fat&#xD;
0.5g Saturated fat&#xD;
20mg Cholesterol&#xD;
135mg Sodium&#xD;
170mg Potassium&#xD;
19g Total carbohydrate&#xD;
&lt;1g Fiber&#xD;
4g Sugar&#xD;
16g Protein&#xD;
Participants will receive Ensure High Protein for 2 weeks pre- and 4 weeks post-operatively. These patients will be instructed to consume 1 serving (16fl oz) of Ensure High Protein daily. They will be provided with this product at a pre-operative clinical visit or have it mailed to their home. Hematologic nutritional values will be measured as specified previously.&#xD;
Descriptive statistics will be used to report baseline characteristics and primary study objectives. Hematologic outcomes will be compared between the control (&quot;NO ENSURE&quot;) and oral supplementation (&quot;ENSURE&quot;) arms for the aforementioned baseline and perioperative variables</description>
    <arm_group_label>Nutritional supplementation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient are current candidates for elective primary total hip and total knee&#xD;
             arthroplasty&#xD;
&#xD;
          2. Patients ≥55 years of age but ≤ 95&#xD;
&#xD;
          3. Patients who meet at least one of the following three laboratory criteria for&#xD;
             malnutrition:&#xD;
&#xD;
        TSerum Albumin: ≤3.5 mg/dl Pre-Albumin: &lt;15 mg/dl Transferrin: &lt;200 mg/dl&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous history of septic arthritis&#xD;
&#xD;
          2. Allergy to oral supplementation&#xD;
&#xD;
          3. Inability to consume oral supplementation&#xD;
&#xD;
          4. Protein malabsorption syndromes&#xD;
&#xD;
          5. Eating disorders&#xD;
&#xD;
          6. End stage renal and hepatic disease&#xD;
&#xD;
          7. Revision surgery, non-elective surgery, hemiarthroplasty, and unicompartmental knee&#xD;
             arthroplasty&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ran Schwarzkopf</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYU Langone</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daniel Warren</last_name>
    <phone>212-598-6245</phone>
    <email>Daniel.waren@nyulangone.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Warren</last_name>
      <phone>212-598-6245</phone>
      <email>daniel.warren@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Ran Schwarzkopf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 23, 2019</study_first_submitted>
  <study_first_submitted_qc>December 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2019</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie the results reported in this article, after deidentification (text, tables, figures, and appendices).</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Beginning 9 months and ending 36 months following article publication or as required by a condition of awards and agreements supporting the research.</ipd_time_frame>
    <ipd_access_criteria>The investigator who proposed to use the data. Upon reasonable request Requests should be directed to Daniel.waren@nyulangone.org. To gain access, data requestors will need to sign a data access agreement.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

